Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 in Mild to Moderate Alzheimer's Disease
NCT06096090Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aldesleukin in Alzheimer's disease (AD) (3 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Safety and Tolerability of IL-2 at 6 months. Started Jan 2022; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06096090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096090.